|
1
|
Rinehardt H, Kassem M, Morgan E, Palettas
M, Stephens JA, Suresh A, Ganju A, Lustberg M, Wesolowski R,
Sardesai S, et al: Assessment of leptomeningeal carcinomatosis
diagnosis, management and outcomes in patients with solid tumors
over a decade of experience. Eur J Breast Health. 17:371–377. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sharma A, Low JT and Kumthekar P: Advances
in the diagnosis and treatment of leptomeningeal disease. Curr
Neurol Neurosci Rep. 22:413–425. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brastianos PK, Strickland MR, Lee EQ, Wang
N, Cohen JV, Chukwueke U, Forst DA, Eichler A, Overmoyer B, Lin NU,
et al: Phase II study of ipilimumab and nivolumab in leptomeningeal
carcinomatosis. Nat Commun. 12:59542021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nguyen A, Nguyen A, Dada OT, Desai PD,
Ricci JC, Godbole NB, Pierre K and Lucke-Wold B: Leptomeningeal
metastasis: A review of the pathophysiology, diagnostic
methodology, and therapeutic landscape. Curr Oncol. 30:5906–5931.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Le Rhun E, Weller M, van den Bent M,
Brandsma D, Furtner J, Rudà R, Schadendorf D, Seoane J, Tonn JC,
Wesseling P, et al: Leptomeningeal metastasis from solid tumours:
EANO-ESMO clinical practice guideline for diagnosis, treatment and
follow-up. ESMO Open. 8:1016242023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Remsik J and Boire A: The path to
leptomeningeal metastasis. Nat Rev Cancer. 24:448–460. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lamba N, Wen PY and Aizer AA: Epidemiology
of brain metastases and leptomeningeal disease. Neuro Oncol.
23:1447–1456. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Y and Li X: Advances in clinical
application of cerebrospinal fluid circulating tumor DNA in
leptomeningeal metastasis of non-small cell lung cancer. Zhongguo
Fei Ai Za Zhi. 27:376–382. 2024.(In Chinese). PubMed/NCBI
|
|
9
|
Im JH, Kim TH, Lee KY, Gwak HS, Lin W,
Park JB, Kim JH, Yoo BC, Park SM, Kwon JW, et al: Exploratory
profiling of extracellular MicroRNAs in cerebrospinal fluid
comparing leptomeningeal metastasis with other central nervous
system tumor statuses. J Clin Med. 10:48602021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin Y, Yu T, Li H, Yin Z and Guo A:
Diagnostic value of locally produced tumor markers and blood brain
barrier integrity in lung cancer patients with leptomeningeal
metastasis. Zhongguo Fei Ai Za Zhi. 24:567–576. 2021.(In Chinese).
PubMed/NCBI
|
|
11
|
Fitzpatrick A, Iravani M, Mills A, Childs
L, Alaguthurai T, Clifford A, Garcia-Murillas I, Van Laere S, Dirix
L, Harries M, et al: Assessing CSF ctDNA to improve diagnostic
accuracy and therapeutic monitoring in breast cancer leptomeningeal
metastasis. Clin Cancer Res. 28:1180–1191. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Glitza IC, Smalley KSM, Brastianos PK,
Davies MA, McCutcheon I, Liu JKC, Ahmed KA, Arrington JA, Evernden
BR, Smalley I, et al: Leptomeningeal disease in melanoma patients:
An update to treatment, challenges, and future directions. Pigment
Cell Melanoma Res. 33:527–541. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stetson D, Ahmed A, Xu X, Nuttall BRB,
Lubinski TJ, Johnson JH, Barrett JC and Dougherty BA: Orthogonal
comparison of four plasma NGS tests with tumor suggests technical
factors are a major source of assay discordance. JCO Precis Oncol.
3:1–9. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mohammadi M, Mohammadi S, Hadizadeh H,
Olfati M, Moradi F, Tanzifi G and Ghaderi S: Brain metastases from
breast cancer using magnetic resonance imaging: A systematic
review. J Med Radiat Sci. 71:133–141. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu JW, Shum M, Qazi MA, Sahgal A, Das S,
Dankner M, Menjak I, Lim-Fat MJ and Jerzak KJ: Cerebral spinal
fluid analyses and therapeutic implications for leptomeningeal
metastatic disease. J Neurooncol. 172:31–40. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li X, Chen K, Li J, Tang X, Ruan H and
Guan M: Diagnostic value of cerebrospinal fluid human epididymis
protein 4 for leptomeningeal metastasis in lung adenocarcinoma.
Front Immunol. 15:13399142024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kharel Z, Stanford S, Hemminger LE,
Schmidt T, Hardy SJ, Zittel J, Mohile NA and Dhaka A: Efficacy of
trastuzumab deruxtecan in treating HER2-low breast cancer
leptomeningeal metastasis: A case report. Per Med. 21:335–339.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lyman KA, Madill E, Thatikunta P,
Threlkeld ZD, Banaei N and Gold CA: An electronic health record
intervention to limit viral testing of cerebrospinal fluid.
Neurohospitalist. 13:173–177. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miao Q, Zheng X, Li L, Zheng X, Zhang L,
Jiang K, Wu S, Wang H, Wu B, Xu Y, et al: Cerebrospinal fluid
circulating tumor DNA contributes to the detection and
characterization of leptomeningeal metastasis in non-small cell
lung cancer. J Neurooncol. 165:517–525. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Im JH, Yoo BC, Lee JH, Lee KY, Kim KH, Kim
JH, Park HJ, Park M, Lee SH, Kwon JW, et al: Experimental
assessment of leptomeningeal metastasis diagnosis in
medulloblastoma using cerebrospinal fluid metabolomic profiles.
Metabolites. 11:8512021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
van Bussel MTJ, Pluim D, Kerklaan BM, Bol
M, Sikorska K, Linders DTC, van den Broek D, Beijnen JH, Schellens
JHM, Brandsma D, et al: Circulating epithelial tumor cell analysis
in CSF in patients with leptomeningeal metastases. Neurology.
94:e521–e528. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Tang X, Gu J, Sun Z, Yang S, Mu Y,
Guan M, Chen K, Liu W, Ruan H and Xu J: CEACAM6 serves as a
biomarker for leptomeningeal metastasis in lung adenocarcinoma.
Cancer Med. 12:4521–4529. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ruan H, Zhou Y, Shen J, Zhai Y, Xu Y, Pi
L, Huang R, Chen K, Li X, Ma W, et al: Circulating tumor cell
characterization of lung cancer brain metastases in the
cerebrospinal fluid through single-cell transcriptome analysis.
Clin Transl Med. 10:e2462020. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Durrani U, Rifai K, Arshad M, Paracha A,
Deol E, Paracha M, Waheed F, Siddiqui Z, Abid A, Mustafic E, et al:
Leptomeningeal metastases in prostate cancer: A review of the
current literature. Curr Urol. 18:159–166. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Benito-Martín A, Jasiulionis MG and
García-Silva S: Extracellular vesicles, melanoma: New perspectives
on tumor microenvironment and metastasis. Front Cell Dev Biol.
10:10619822022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kilian M and Quintana FJ:
Immunosuppressive dura-derived macrophages in leptomeningeal
metastasis. Nat Cancer. 5:1791–1792. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao J, Zeng R, Li X, Lu Y, Wang Z, Peng
H, Chen H, Fu M, Zhang Y, Huang Y, et al: Dura immunity configures
leptomeningeal metastasis immunosuppression for cerebrospinal fluid
barrier invasion. Nat Cancer. 5:1940–1961. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Galicia N, Díez P, Dégano RM, Guest PC,
Ibarrola N and Fuentes M: Proteomic biomarker identification in
cerebrospinal fluid for leptomeningeal metastases with neurological
complications. Adv Exp Med Biol. 974:85–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Novegno F, Umana G, Granaroli P, Borri F,
Orlandi A and Lunardi P: Current management of central nervous
system metastasis from cholangiocarcinoma: The neurosurgical
perspective. Literature review. Br J Neurosurg. 34:575–583. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Yang X, Li NJ and Xue JX:
Leptomeningeal metastases in non-small cell lung cancer: Diagnosis
and treatment. Lung Cancer. 174:1–13. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hyun JW, Shin HS, Kim SH, Kong SY, Yoo H,
Gwak HS and Kim HJ: CYFRA 21-1 levels in cerebrospinal fluid as a
putative therapeutic monitoring biomarker for patients with
leptomeningeal carcinomatosis: A pilot study. Cancer Biomark.
28:81–89. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hyun JW, Park JH, Kang BG, Park EY, Park
B, Joo J, Kim JK, Kim SH, Jeong JH, Lee HW, et al: Diagnostic and
prognostic values of cerebrospinal fluid CYFRA 21-1 in patients
with leptomeningeal carcinomatosis. Oncotarget. 8:53326–53335.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hyun JW, Kim Y, Kim KH, Kim SH, Park EY,
Youn JH, Yoo H, Gwak HS and Kim HJ: Cerebrospinal fluid
neurofilament light chain as a potential prognostic biomarker for
leptomeningeal metastasis. Oncol Lett. 24:4282022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Walker JG, Armstrong TS, O'Brien BJ,
Gilbert MR, Casarez RL, Fagundes C, Heijnen CJ, Andersen CR, Yuan
Y, Wu J and LoBiondo-Wood G: Associations of meaning of illness
with psychosocial, clinical, and immunological characteristics in
patients with Leptomeningeal metastasis. Compreh
Psychoneuroendocrinol. 8:1000992021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hasanov M, Milton DR, Davies AB, Sirmans
E, Saberian C, Posada EL, Opusunju S, Gershenwald JE, Torres-Cabala
CA, Burton EM, et al: Changes in outcomes and factors associated
with survival in melanoma patients with brain metastases. Neuro
Oncol. 25:1310–1320. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Twijnstra A, van Zanten AP, Nooyen WJ and
de Visser BW: Sensitivity and specificity of single and combined
tumour markers in the diagnosis of leptomeningeal metastasis from
breast cancer. J Neuro Neurosurg Psychiatry. 49:1246–1250. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brandsma D, Voest EE, de Jager W, Bonfrer
H, Algra A, Boogerd W, Korse T, Reijneveld JC, Verbeek MM, Rijkers
G and Taphoorn MJ: CSF protein profiling using Multiplex
Immuno-assay: A potential new diagnostic tool for leptomeningeal
metastases. J Neurol. 253:1177–1184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Martirosian V, Deshpande K, Zhou H, Shen
K, Smith K, Northcott P, Lin M, Stepanosyan V, Das D, Remsik J, et
al: Medulloblastoma uses GABA transaminase to survive in the
cerebrospinal fluid microenvironment and promote leptomeningeal
dissemination. Cell Rep. 35:1093022021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liang SK, Liao WY, Shih JY, Hsu CL, Yang
CY, Wu SG, Lin YT, Wen YF, Chen LC, Chen YF, et al: Clinical
utility and predictive value of cerebrospinal fluid cell-free DNA
profiling in non-small cell lung cancer patients with
leptomeningeal metastasis. Neoplasia. 60:1011132024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pentsova E: Applications of cerebrospinal
fluid circulating tumor cells and circulating tumor-derived DNA in
diagnosis, prognosis, and personalized treatment of CNS metastases.
Front Oncol. 14:14093832024. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li H, Xie Y, Lin Y, Yu T and Yin Z:
Different gene mutation spectrum of the paired csf and plasma
samples in lung adenocarcinoma with leptomeningeal metastases: The
liquid biopsy based on circulating tumor DNA. Zhongguo Fei Ai Za
Zhi. 23:646–654. 2020.PubMed/NCBI
|
|
42
|
Nie N, Zhou H, Zhang K, Liu L, Luo N, Wang
R, Li X, Zhu M, Hu C, Wang Y, et al: Genotyping of cerebrospinal
fluid in lung cancer patients with leptomeningeal metastasis.
Thorac Cancer. 13:2574–2583. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang H, Wen L, Zhao C, Chen J, Zhou Z and
Zhou C, Cai L and Zhou C: Cerebrospinal fluid-derived circulating
tumor DNA is more comprehensive than plasma in NSCLC patients with
leptomeningeal metastases regardless of extracranial evolution.
Heliyon. 8:e123742022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu Q, Ye L, Huang L, Zhou L, Chen X, Ye M,
Wu G, Zhan P, Lv T and Song Y: Serum Exosomal miRNA might be a
novel liquid biopsy to identify leptomeningeal metastasis in
non-small cell lung cancer. Onco Targets Ther. 14:2327–2335. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Im JH, Lee KY, Seo Y, Rhim J, Dho YS, Yoo
BC, Park JB, Shin SH, Yoo H, Kim JH and Gwak HS: Extracellular
vesicles from cerebrospinal fluid of leptomeningeal metastasis
patients deliver MiR-21 and induce methotrexate resistance in lung
cancer cells. Int J Mol Sci. 25:3124–2024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee KY, Seo Y, Im JH, Rhim J, Baek W, Kim
S, Kwon JW, Yoo BC, Shin SH, Yoo H, et al: Molecular signature of
extracellular vesicular small non-coding RNAs derived from
cerebrospinal fluid of leptomeningeal metastasis patients:
Functional implication of miR-21 and other Small RNAs in cancer
malignancy. Cancers (Basel). 13:2092021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jin J, Cui Y, Niu H, Lin Y, Wu X, Qi X,
Bai K, Zhang Y, Wang Y and Bu H: NSCLC extracellular vesicles
containing miR-374a-5p promote leptomeningeal metastasis by
influencing blood-brain barrier permeability. Mol Cancer Res.
22:699–710. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Angus L, Deger T, Jager A, Martens JWM, de
Weerd V, van Heuvel I, van den Bent MJ, Smitt PAE, Kros JM, Bindels
EMJ, et al: Detection of aneuploidy in cerebrospinal fluid from
patients with breast cancer can improve diagnosis of leptomeningeal
metastases. Clin Cancer Res. 27:2798–2806. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang L, Fang K, Ren H, Fan S, Wang J and
Guan H: Comparison of the diagnostic significance of cerebrospinal
fluid metagenomic next-generation sequencing copy number variation
analysis and cytology in leptomeningeal malignancy. BMC Neurol.
24:2232024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lukow DA and Sheltzer JM: Chromosomal
instability and aneuploidy as causes of cancer drug resistance.
Trends Cancer. 8:43–53. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cohen-Nowak AJ, Hill VB and Kumthekar P:
Diagnostics and screening in breast cancer with brain and
leptomeningeal metastasis: A review of the literature. Cancers
(Basel). 16:36862024. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pattanaik J, Goel V, Sehrawat P, Rathore
R, Singh RK, Garg A and Biswas A: Leptomeningeal carcinomatosis in
a patient with recurrent unresectable squamous cell carcinoma of
the retromolar trigone-a brief report. J Egypt Natl Cancer Inst.
34:462022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cuadra JD, de Vera MT, Carrasco EG and
Martín MI: Adenoid cystic carcinoma with a leptomeningeal
dissemination in a ‘wash’ pattern. BMJ Case Rep. 14:e2471552021.
View Article : Google Scholar
|
|
54
|
Wlock R, Patel K, Patel M and Tanase A:
Leptomeningeal carcinomatosis secondary to a gastrointestinal
stromal tumor. Cureus. 13:e162122021.PubMed/NCBI
|
|
55
|
Serra E, Abarzua-Araya Á, Arance A,
Martin-Huertas R, Aya F, Olondo ML, Rizo-Potau D, Malvehy J, Puig
S, Carrera C and Podlipnik S: Predictive and prognostic factors in
melanoma central nervous system metastases-a cohort study. Cancers
(Basel). 16:22722024. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Legrand C, Bour JM, Jacob C, Capiaumont J,
Martial A, Marc A, Wudtke M, Kretzmer G, Demangel C and Duval D:
Lactate dehydrogenase (LDH) activity of the cultured eukaryotic
cells as marker of the number of dead cells in the medium
[corrected]. J Biotechnol. 25:231–243. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
An YJ, Cho HR, Kim TM, Keam B, Kim JW, Wen
H, Park CK, Lee SH, Im SA, Kim JE, et al: An NMR metabolomics
approach for the diagnosis of leptomeningeal carcinomatosis in lung
adenocarcinoma cancer patients. Int J Cancer. 136:162–171. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Paisana E, Cascão R, Custódia C, Qin N,
Picard D, Pauck D, Carvalho T, Ruivo P, Barreto C, Doutel D, et al:
UBE2C promotes leptomeningeal dissemination and is a therapeutic
target in brain metastatic disease. Neuro Oncol Adv. 5:vdad0482023.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bönig L, Möhn N, Ahlbrecht J, Wurster U,
Raab P, Puppe W, Sühs KW, Stangel M, Skripuletz T and
Schwenkenbecher P: Leptomeningeal metastasis: The role of
cerebrospinal fluid diagnostics. Front Neurol. 10:8392019.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chi Y, Remsik J, Kiseliovas V, Derderian
C, Sener U, Alghader M, Saadeh F, Nikishina K, Bale T,
Iacobuzio-Donahue C, et al: Cancer cells deploy lipocalin-2 to
collect limiting iron in leptomeningeal metastasis. Science.
369:276–282. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lupica-Tondo GL, Arner EN, Mogilenko DA
and Voss K: Immunometabolism of ferroptosis in the tumor
microenvironment. Front Oncol. 14:14413382024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sivanand S, Gultekin Y, Winter PS,
Vermeulen SY, Tchourine KM, Abbott KL, Danai LV, Gourgue F, Do BT,
Crowder K, et al: Cancer tissue of origin constrains the growth and
metabolism of metastases. Nat Metab. 6:1668–1681. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Malani R, Fleisher M, Kumthekar P, Lin X,
Omuro A, Groves MD, Lin NU, Melisko M, Lassman AB, Jeyapalan S, et
al: Cerebrospinal fluid circulating tumor cells as a quantifiable
measurement of leptomeningeal metastases in patients with HER2
positive cancer. J Neurooncol. 148:599–606. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Malhotra J, Muddasani R, Fricke J,
Mambetsariev I, Reyes A, Babikian R, Dingal ST, Kim P, Massarelli
E, Feldman L, et al: Clinical utility of a circulating tumor
cell-based cerebrospinal fluid assay in the diagnosis and molecular
analysis of leptomeningeal disease in patients with advanced
non-small cell lung cancer. JCO Precis Oncol. 8:e24003732024.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Darlix A, Cayrefourcq L, Pouderoux S, de
Champfleur NM, Bievelez A, Jacot W, Leaha C, Thezenas S and
Alix-Panabières C: Detection of circulating tumor cells in
cerebrospinal fluid of patients with suspected breast cancer
leptomeningeal metastases: A prospective study. Clin Chem.
68:1311–1322. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Diaz M, Singh P, Kotchetkov IS, Skakodub
A, Meng A, Tamer C, Young RJ, Reiner AS, Panageas KS, Ramanathan LV
and Pentsova E: Quantitative assessment of circulating tumor cells
in cerebrospinal fluid as a clinical tool to predict survival in
leptomeningeal metastases. J Neuro Oncol. 157:81–90. 2022.
View Article : Google Scholar
|
|
67
|
Nevel KS, Wilcox JA, Robell LJ and Umemura
Y: The utility of liquid biopsy in central nervous system
malignancies. Curr Oncol Rep. 20:602018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Congur I, Koni E, Onat OE and Keskin ZT:
Meta-analysis of commonly mutated genes in leptomeningeal
carcinomatosis. PeerJ. 11:e152502023. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Cho JH, Sim MH, Kim SY, Kim K, Lee T, Lee
J, Kang WK and Kim ST: Analysis of intrapatient heterogeneity of
circulating tumor cells at the single-cell level in the
cerebrospinal fluid of a patient with metastatic gastric cancer. J
Cancer Res Ther. 17:1047–1051. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ma C, Yang X, Xing W, Yu H, Si T and Guo
Z: Detection of circulating tumor DNA from non-small cell lung
cancer brain metastasis in cerebrospinal fluid samples. Thorac
Cancer. 11:588–593. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cordone I, Masi S, Summa V, Carosi M,
Vidiri A, Fabi A, Pasquale A, Conti L, Rosito I, Carapella CM, et
al: Overexpression of syndecan-1, MUC-1, putative stem cell markers
in breast cancer leptomeningeal metastasis: A cerebrospinal fluid
flow cytometry study. Breast Cancer Res. 19:462017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Marowsky M, Müller V, Schmalfeldt B,
Riecke K, Witzel I and Laakmann E: Intrathecal therapy options for
meningeal carcinomatosis. Geburtshilfe Frauenheilk. 84:59–67. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Le Rhun E, Wallet J, Mailliez A, Le Deley
MC, Rodrigues I, Boulanger T, Lorgis V, Barrière J, Robin YM,
Weller M and Bonneterre J: Intrathecal liposomal cytarabine plus
systemic therapy versus systemic chemotherapy alone for newly
diagnosed leptomeningeal metastasis from breast cancer. Neuro
Oncol. 22:524–538. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Bian DJH, Lazaratos AM, Maritan SM,
Quaiattini A, Zeng Z, Zhu Z, Sener U, Malani R, Kim YJ, Ichihara E,
et al: Osimertinib is associated with improved outcomes in
pre-treated non-small cell lung cancer leptomeningeal metastases: A
systematic review and meta-analysiss. Heliyon. 10:e296682024.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Sherman WJ, Romiti E, Michaelides L,
Moniz-Garcia D, Chaichana KL, Quiñones-Hinojosa A and Porter AB:
Systemic therapy for melanoma brain and leptomeningeal metastases.
Curr Treat Options Oncol. 24:1962–1977. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Mizumatsu S, Wakabayashi K and Terashima
Y: Palliative treatment of leptomeningeal carcinomatosis from renal
cell carcinoma with local cyberknife radiotherapy and systemic
pazopanib therapy: A case report. Cureus. 16:e540252024.PubMed/NCBI
|
|
77
|
Chiang CL, Ho HL, Yeh YC, Lee CC, Huang
HC, Shen CI, Luo YH, Chen YM, Chiu CH and Chou TY: Efficacy of
different platforms in detecting EGFR mutations using cerebrospinal
fluid cell-free DNA from non-small-cell lung cancer patients with
leptomeningeal metastases. Thorac Cancer. 14:1251–1259. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yu C, Xu T, Fang H, Wang X, Liu N, Yang L
and Fang S: High-dose furmonertinib combined with intraventricular
chemotherapy as salvage therapy for leptomeningeal metastasis from
EGFR exon 20 insertion-mutated lung cancer. J Neurooncol.
169:203–213. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Bai K, Chen X, Qi X, Zhang Y, Zou Y, Li J,
Yu L, Li Y, Jiang J, Yang Y, et al: Cerebrospinal fluid circulating
tumour DNA genotyping and survival analysis in lung adenocarcinoma
with leptomeningeal metastases. J Neurooncol. 165:149–160. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zhong W, Wu L, Huang L, Wang J, Shi H and
Wu S: Double-dose osimertinib combined with intrathecal injection
of pemetrexed improves the efficacy of EGFR-mutant non-small cell
lung cancer and leptomeningeal metastasis: Case report and
literature review. Front Oncol. 14:13774512024. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Dekker LJ, Boogerd W, Stockhammer G,
Dalebout JC, Siccama I, Zheng P, Bonfrer JM, Verschuuren JJ,
Jenster G, Verbeek MM, et al: MALDI-TOF mass spectrometry analysis
of cerebrospinal fluid tryptic peptide profiles to diagnose
leptomeningeal metastases in patients with breast cancer. Mol Cell
Proteomics. 4:1341–1349. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Xu Y, Huang Z, Yu X, Chen K and Fan Y:
Integrated genomic and DNA methylation analysis of patients with
advanced non-small cell lung cancer with brain metastases. Mol
Brain. 14:1762021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Xing L, Pan Y, Shi Y, Shu Y, Feng J, Li W,
Cao L, Wang L, Gu W, Song Y, et al: Biomarkers of osimertinib
response in patients with refractory and EGFR-T790M-positive
non-small cell lung cancer and central nervous system metastases:
The APOLLO study. Clin Cancer Res. 26:6168–6175. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Chen H, Yang S, Wang L, Wu Y, Wu Y, Ma S,
He Z, Zhang C, Liu Y, Tang H, et al: High-Dose furmonertinib in
patients with EGFR-Mutated NSCLC and leptomeningeal metastases: A
prospective real-world study. J Thorac Oncol. 20:65–75. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wang Y, Deng H, Xin S, Zhang K, Shi R and
Bao X: Prognostic and predictive value of three DNA methylation
signatures in lung adenocarcinoma. Front Genet. 10:3492019.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Xia S, Ye J and Chen Y, Lizaso A, Huang L,
Shi L, Su J, Han-Zhang H, Chuai S, Li L and Chen Y: Parallel serial
assessment of somatic mutation and methylation profile from
circulating tumor DNA predicts treatment response and impending
disease progression in osimertinib-treated lung adenocarcinoma
patients. Transl Lung Cancer Res. 8:1016–1028. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Lee KY, Im JH, Lin W, Gwak HS, Kim JH, Yoo
BC, Kim TH, Park JB, Park HJ, Kim HJ, et al: Nanoparticles in 472
human cerebrospinal fluid: Changes in extracellular vesicle
concentration and miR-21 expression as a biomarker for
leptomeningeal metastasis. Cancers (Basel). 12:27452020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Sawada H, Taniguchi Y, Iizuka S, Ikeda T,
Aga M, Hamakawa Y, Miyazaki K, Misumi Y, Agemi Y, Nakamura Y, et
al: Entrectinib response to ROS1-fusion-positive non-small-cell
lung cancer that progressed on crizotinib with leptomeningeal
metastasis: A case report. Case Rep Oncol. 16:1558–1567. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wijetunga NA, Goglia AG, Weinhold N,
Berger MF, Cislo M, Higginson DS, Chabot K, Osman AM, Schaff L,
Pentsova E, et al: Dynamic mutational landscape of cerebrospinal
fluid circulating tumor DNA and predictors of survival after proton
craniospinal irradiation for leptomeningeal metastases. Clin Cancer
Res. 29:775–783. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Boire A, Brandsma D, Brastianos PK, Le
Rhun E, Ahluwalia M, Junck L, Glantz M, Groves MD, Lee EQ, Lin N,
et al: Liquid biopsy in central nervous system metastases: A RANO
review and proposals for clinical applications. Neuro Oncol.
21:571–584. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Park S, Lee MH, Seong M, Kim ST, Kang JH,
Cho BC, Lee KH, Cho EK, Sun JM, Lee SH, et al: A phase II,
multicenter, two cohort study of 160 mg osimertinib in EGFR
T790M-positive non-small-cell lung cancer patients with brain
metastases or leptomeningeal disease who progressed on prior EGFR
TKI therapy. Ann Oncol. 31:1397–1404. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Smalley I, Law V, Wyatt C, Evernden B,
Fang B, Koomen JM, Welsh EA, Macaulay RJB, Forsyth PA and Smalley
KSM: Proteomic analysis of CSF from patients with leptomeningeal
melanoma metastases identifies signatures associated with disease
progression and therapeutic resistance. Clin Cancer Res.
26:2163–2175. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Li G, Fang M, Zhou Y, Liu X, Tian P and
Mei F: Afatinib overcoming resistance to icotinib and osimertinib
in NSCLC with leptomeningeal metastasis in patients with acquired
EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
Heliyon. 9:e206902023. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Koyuncuer A, Varol E, Yağcioğlu BS, Bükte
Y and Sakcı Z: Cerebrospinal fluid-dissemination of a ovarian clear
cell carcinoma: A leptomeningial carcinomatosis with diagnostic
challenges. Diagn Cytopathol. 51:E228–E231. 2023. View Article : Google Scholar : PubMed/NCBI
|
